Align Technology (ALGN) is a publicly traded Healthcare sector company. As of October 28, 2026, ALGN trades at $152.11 with a market cap of $10.79B and a P/E ratio of 24.68. ALGN moved +0.92% today. Year to date, ALGN is -1.54%; over the trailing twelve months it is +15.38%. Its 52-week range spans $122.00 to $208.31. Analyst consensus is buy with an average price target of $194.90. Rallies surfaces ALGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Align cuts 2026 revenue outlook and names Jennifer L. Davis CEO-elect: Align lowered its 2026 revenue outlook to $4.11 billion-$4.13 billion, citing weaker scanner revenue expectations, slightly lower Clear Aligner volume and pricing assumptions, and foreign exchange effects. Jennifer L. Davis will become president and CEO on December 31, 2026, when Joseph M. Hogan steps down from the role and board.
| Metric | Value |
|---|---|
| Price | $152.11 |
| Market Cap | $10.79B |
| P/E Ratio | 24.68 |
| EPS | $5.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $208.31 |
| 52-Week Low | $122.00 |
| Volume | 1.10M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.14B |
| Net Income | $413.58M |
| Gross Margin | 68.05% |
13 analysts cover ALGN: 0 strong buy, 8 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $194.90.